dolutegravir prodrug

Dolutegravir prodrugs are chemically modified forms of the HIV-1 integrase strand transfer inhibitor dolutegravir (DTG), designed to improve pharmacokinetic properties and enable long-acting antiretroviral therapy. These prodrugs include monomeric ester derivatives (such as NM2DTG) and dimeric forms (such as NM4DTG), which are synthesized by covalently linking one or two DTG molecules to fatty diacids. The modifications aim to extend the apparent half-life of DTG in vivo and facilitate depot formulations for sustained drug release. Dolutegravir acts by inhibiting HIV-1 integrase, blocking the integration of viral DNA into host cells—a critical step in HIV replication[9]. The development of these long-acting formulations addresses challenges with daily adherence in lifelong antiretroviral therapy.

Other names

DTG prodrugdimeric dolutegravir prodrug